Citi raised the firm’s price target on Immunovant to $33 from $28 and keeps a Buy rating on the shares post the fiscal Q1 update. The analyst believes the risk/reward is “skewed favorably” into the SAD data as the firm’s analysis suggests albumin changes in NHPs appear to translate to changes with similar magnitudes in humans across FcRN inhibitors with available data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMVT:
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
- Immunovant reports Q1 EPS (57c), consensus (45c)
- Citi opens ‘positive catalyst watch’ on Immunovant into data
- Immunovant price target raised to $33 from $27 at Wells Fargo
- Immunovant price target raised to $34 at Stifel after Argenx data